Relmada Therapeutics, Inc. RLMD Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s accrued liabilities?
- Relmada Therapeutics, Inc. (RLMD) reported accrued liabilities of -$1.56M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s accrued liabilities changed year-over-year?
- Relmada Therapeutics, Inc.'s accrued liabilities increased by 28.9% year-over-year, from -$2.19M to -$1.56M.
- What does accrued liabilities mean?
- Represents the net change in obligations for expenses incurred but not yet paid at the end of the reporting period. This metric reflects the company's short-term liability management and timing of cash outflows for operational costs.